Details of the Drug

General Information of Drug (ID: DM6NPUJ)

Drug Name
NLX-P101
Synonyms RAAV-GAD; STN AAV-GAD gene therapy, Neurologix; Subthalamic nucleus AAV-glutamic acid decarboxylase gene therapy, Neurologix; NLX gene therapy (Parkinson's), Neurologix
Indication
Disease Entry ICD 11 Status REF
Parkinson disease 8A00.0 Discontinued in Phase 2 [1]
Cross-matching ID
DrugBank ID
DB05924
TTD ID
D0VT0T

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Glutamate decarboxylase (GLUL) TTURQ2G GLNA_HUMAN Modulator [2]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Molecular Expression Atlas of This Drug

The Studied Disease Parkinson disease
ICD Disease Classification 8A00.0
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
Glutamate decarboxylase (GLUL) DTT GLUL 2.45E-01 -0.23 -0.4
Molecular Expression Atlas (MEA) Jump to Detail Molecular Expression Atlas of This Drug

References

1 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800017938)
2 NLX-P101, an adeno-associated virus gene therapy encoding glutamic acid decarboxylase, for the potential treatment of Parkinson's disease. Curr Opin Investig Drugs. 2010 Jul;11(7):813-22.